Blue Sky heaven as Sortera Bio and AstraZeneca take collaboration to fresh heights
In terms of age and maturity they are at opposite ends of the spectrum but the companies have found common ground in a budding alliance designed to leverage Sortera Bio's innovative Deep Screening platform to identify early drug hits to potential drug targets and accelerate the discovery and development of novel biologics.
The collaboration builds on an existing relationship between the companies which began through the Medical Research Council Laboratory of Molecular Biology (MRC LMB)-AstraZeneca Blue Sky Collaboration, where Sortera's technology was initially developed.
Under this new agreement, AstraZeneca will continue to access Sortera Bio's proprietary Deep Screening platform, which enables the precise identification of potential therapeutic candidates with desirable drug-like properties by experimentally collecting sequence and functional data for hundreds of millions of biologics in a single experiment.
Ben Porebski, CEO-CTO of Sortera Bio, says: "We are thrilled to expand our collaboration with AstraZeneca, further building on the successful LMB-AstraZeneca Blue Sky initiative that helped develop our foundational technology.
"This collaboration represents a significant milestone in our mission to redefine early biologics discovery and engineering. By combining our Deep Screening capabilities with AstraZeneca's expertise in AI assisted biologics discovery, we aim to rapidly discover precision biologics that have the potential to benefit patients."
The collaboration will enable both companies to utilise their complementary strengths to drive innovation in biologics discovery. AstraZeneca's extensive capabilities in drug discovery and development will help to realise the potential of Sortera Bio's innovative Deep Screening platform and support its application, with the potential to address some of the most pressing challenges in healthcare.
Sortera Bio is based on intellectual property developed at the MRC Laboratory of Molecular Biology. The company is focused on accelerating the discovery of biologics via its proprietary Deep Screening platform and is dedicated to delivering transformative solutions in biologics discovery to meet the needs of patients worldwide.